Skip to content

A clinical study to establish the safety and efficacy of a natural formulation -Asdamarin in dyspepsia patients

A randomized, double blind, placebo controlled, parallel group study to evaluate the Safety and Efficacy of Asdamarin in subjects with non- ulcer functional Dyspepsia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013993
Enrollment
70
Registered
2018-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients diagnosed with non - ulcer functional dyspepsia

Interventions

Intervention1: Asdamarin: Asdamrin 250mg (400mg Capsules) 2 times per day for 7 days Control Intervention1: Placebo: 400 mg of maltodextrin 2 times per day for 07 days

Sponsors

Vidya Herbs Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fulfilling Rome III diagnostic criteria for functional dyspepsia 2. Must be willing and able to give informed consent and comply with the study procedures 3. Female subjects who are non-pregnant, non-lactating, postmenopausal, surgically sterilized, or using a medically acceptable form of birth control, as determined by the investigator

Exclusion criteria

Exclusion criteria: 1 History of peptic ulcer, gastro oesophageal reflux disease, gastro intestinal surgery or any other clinically significant gastro intestinal disease, gastrointestinal bleeding, mechanical obstruction, perforation, gastrointestinal cancer. 2 Subjects who have taken antibiotics or any other drugs in last 2 weeks with primary site of action in the gastro intestinal tract 3 History of psychiatric illness 4 History of congestive heart failure or uncontrolled hypertension 5 Subjects with abnormal haematological or biochemical parameters 6 Pregnant or lactating women or those planning for conception 7 Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study

Design outcomes

Primary

MeasureTime frame
Changes in Gastro Intestinal Symptom Rating Scale, Glasgow Dyspepsia Severity Score ,Nepean Dyspepsia Index from baseline to end of the studyTimepoint: Day 0, Day 07

Secondary

MeasureTime frame
Change in Hematological and Biochemical Safety ParametersTimepoint: Day 0, Day 07;Incidence of Adverse EventsTimepoint: Day 07

Countries

India

Contacts

Public ContactJestin V Thomas

Leads Clinical Research and Bio Services Private Limited

jestin.leadsclinbio@gmail.com9845125293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 14, 2026